Deallus

Deallus Partner, Jack Florio will be speaking at the prestigious Drug Discovery Innovation Programme, taking place in San Diego, 3-4 March. Bringing together the top minds in drug discovery to explore the future of pharmaceutical science, #DDIP2025 offers a unique opportunity to exchange insights with key industry leaders and accelerate the pace of drug discovery. If you’re attending #DDIP2025 and would like to connect with Jack, please do get in touch to book a time to meet. You can get in touch here: https://lnkd.in/ehBub766 You can find out more about #DDIP here: https://lnkd.in/eVqyQx6V   #DDIP #DrugDiscovery #Innovation #Biotech  #conference #speaking

As the genitourinary oncology community gathers for #ASCOGU, Deallus is looking forward to joining the discussions, especially as we see the latest data driving changes in the treatment landscape of prostate, renal, and bladder cancer therapy. Each new development brings fresh opportunities to improve patient outcomes through effective, personalised treatments. These insights not only advance clinical care but also help us identify solutions to key challenges faced by both patients and our clients. Here are some key updates the team at Deallus is particularly eager to see:   Prostate Cancer - Pfizer’s TALAPRO-2 (Phase 3): Final overall survival (OS) data on talazoparib + enzalutamide as a first-line treatment for mCRPC – could talazoparib expand its label into a wider patient population? - Pfizer’s EZH2 Inhibition + Enzalutamide: A novel combination featuring mevrometostat, targeting epigenetics in mCRPC – how will EZH2 inhibitors fit into the future landscape?   Renal Cancer - Exelixis’s COSMIC-313 (Phase 3): Final results on cabozantinib + nivolumab + ipilimumab in first-line advanced RCC – will this triple combination change the standard of care? - Merck’s KEYMAKER-U03 (Pembrolizumab + Targeted Therapy): Exploring new combination strategies for advanced clear cell RCC – could this improve the prognosis for ccRCC patients?   Bladder Cancer Updates from two antibody drug-conjugates - Astellas/Pfizer’s EV-302 (Phase 3): Updated data on enfortumab vedotin + pembrolizumab vs chemotherapy in 1L metastatic urothelial carcinoma – could this be the new frontline standard? - Daiichi Sankyo/AstraZeneca’s Dato-DXd (TROPION-PanTumor01): Updated results in advanced urothelial cancer – an exciting avenue for TROP2 targeted therapies! What are you most looking forward to at #ASCOGU 2025? Comment below and discuss! If you'd like to meet us at the conference, or want to arrange a meeting to discuss how we can help you, do get in touch: https://lnkd.in/ehBub766 #GUOncology #ASCOGU25 #ProstateCancer #RenalCellCarcinoma #BladderCancer #OncologyResearch

Today, 4th February, is World Cancer Day. At Deallus we are looking forward to 2025 and optimistic that our clients will continue to make great progress in developing new and innovative therapies for cancer patients worldwide. Here are a few things that we are particularly excited about for the coming year:   Emerging Modalities and MoAs: Cancer treatments are becoming increasingly diversified across MoAs, and this will only increase in 2025, with therapies such as cancer vaccines, cytokines, and radioligand therapies all in development   Precision Medicine and Diagnostics: As non-invasive diagnostic tests such as liquid biopsies continue to develop and improve, so too will the opportunities for further treatment personalisation and more accurate, timely detection of recurrence   AI and ML: As with almost all industries, AI has the potential to revolutionise aspects of the patient journey, from predicting cancer risk and enabling earlier diagnosis, to predicting outcomes and recommending optimal treatment outcomes. 2025 is likely to see AI tools increasingly incorporated into clinical studies, ahead of more widespread adoption in the clinic over the coming years.   Our experience and expertise continues to support clients at every stage of research and development of cancer treatments. If you’d like to find out more, please get in touch here: https://lnkd.in/ehBub766   #worldcancerday #lifesciences #patientcare #cancerexpertise #clientsupport #innovation

We are delighted to announce that Deallus will be attending ASCO GI 2025, where advancements in GI research will be presented. We are eager to engage with experts in the field and share impactful insights from the conference. Among the accepted abstracts, we wanted to highlight a few noteworthy titles, particularly involving studies exploring the potential of anti-CTLA-4 combinations. Additional evidence would provide confidence for oncologists to evaluate the trade-off between enhanced efficacy and additional toxicity, especially for cancer patients in the earlier lines. Hepatocellular Carcinoma Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) therapy for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW expanded analyses Esophageal Squamous Cell Carcinoma Preliminary results from the multicenter, randomised phase III trial (SCIENCE): Comparing chemotherapy plus sintilimab and chemoradiotherapy plus sintilimab versus chemoradiotherapy for neoadjuvant treatment in resectable locally advanced esophageal squamous cell carcinoma Colorectal Cancer - First results of nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) from CheckMate 8HW - BREAKWATER: Analysis of first-line encorafenib + cetuximab + chemotherapy in BRAF V600E-mutant metastatic colorectal cancer ·      Preliminary results from a randomized, open-label, phase 2 study of botensilimab (BOT) with or without balstilimab (BAL) in refractory microsatellite stable metastatic colorectal cancer with no liver metastases (MSS mCRC NLM) If you'd like to arrange a meeting with us, get in touch here: https://lnkd.in/ehBub766 You can find out more about the conference here: https://lnkd.in/gwCs3nqb #conference #meetus #ascogi2025 #cancer #gastrointestinal #lifescience #makingadifference #patientfirst

Deallus is pleased to announce it has been acquired by GlobalData Healthcare. You can read the full press release here: https://lnkd.in/e95J5cJa Our combined vision is to become the world’s #1 trusted source of strategic industry intelligence and advice in the pharmaceutical market. Bringing Deallus and GlobalData Healthcare together allows us to combine our existing capabilities to serve our clients with a broader and deeper set of offerings. Pete Hempshall, CEO of Deallus states: “We are very excited to join the GlobalData family both for our teams and our clients. Joining GlobalData Healthcare will enhance the offerings and solutions we can provide in the future as we leverage GlobalData’s extensive Research and Analytics capability, data and tools and significant investment in AI. Our immediate priority is to ensure we capture the benefits of our combined strength to deepen our insights and better support our clients as they navigate an increasingly complex competitive landscape.” Read the full press release here: https://lnkd.in/e95J5cJa #acquisition #expertise #clientvalue #ambition #growth

We wish all our clients, colleagues, and friends across the world, a very happy holidays. We look forward to 2025 as a year of success and prosperity for all. You can see the Deallus festive animation here: https://lnkd.in/ejMEECfr #holidays #festive #animation #friends #clients #colleagues #rest

In our final blog of the year, Uncertainty is Here to Stay, Ulrike Meier and Eugénie Joanny explore how, in another turbulent year, uncertainty seems here to stay and what this means for the pharma sector. You can read the blog here: https://lnkd.in/exQ6EP63   Uncertainty is inherent to most businesses, particularly in Pharma, where bench-to-bedside timelines can span a decade, and current decisions shape long-term success. Intensified uncertainty challenges our clients’ risk management and decision-making in a world where unpredictability and agility are the new normal.   We find three approaches instrumental in building robust assumptions for proactive, dynamic, and future-fit scenario planning. Read what these are, and more, in our blog here: https://lnkd.in/exQ6EP63   #blog #uncertainty #thenewnormal #proactivedecisionmaking #riskmanagement #futurefit

We wish all our clients, colleagues, and friends across the world, a very happy holidays. We look forward to 2025 as a year of success and prosperity for all. You can see the Deallus festive animation here: https://lnkd.in/ejMEECfr #holidays #festive #animation #friends #clients #colleagues #rest

As part of our 20th anniversary celebrations we have been delighted to showcase some of our alumni who have all played a part in our journey so far. We are very proud of all our Deallus team - past, present and future.   We would like to thank Suffwan Eltom, Philip Miller, Carolyn Ng, Cyrus Arman, PhD MBA, Ines H., Carole Bruckler, PhD, Chester Wong, Stephanie Newman, Hiroyuki Onoda, and Andy Walton for taking part in our alumni series over the past 12 months. It’s been a privilege to celebrate your time at Deallus, hear how your experiences at Deallus influenced and impacted your career choices to date, and to see you thriving in your current roles.   We will be continuing our alumni programme through 2025. Do get in touch if you would like to be involved or to find out more. https://lnkd.in/ehBub766   We wish all our alumni a wonderful festive season.   #alumni #careersuccess #impact #learning #celebrating #influence #pride #thankyou

Deallus is delighted to be attending the American Society of Hematology (ASH) 2024 Congress. Taking place in San Diego from 7th to 10th December, we look forward to discussing the latest trends and data readouts in the hematology space. Sessions we are particularly interested in, and which we expect could have a big impact on the treatment of a variety of different hematological cancers, include: 1. In follicular lymphoma (FL), Incyte Corporation will share the results of the Phase 3 inMIND study evaluating tafasitamab (Monjuvi) in combination with lenalidomide and rituximab (LBA-1), following positive topline results shared back in August. This is the first study to validate the combination of two mAbs (anti-CD19 + anti-CD20) in the treatment of lymphoma, providing a new approach for patients who have failed prior therapy. 2. In chronic lymphocytic leukemia (CLL), AZ is presenting an interim analysis from the open-label Phase 3 AMPLIFY study of fixed duration acalabrutinib (Calquence) in combination with venetoclax ± obinutuzumab in the first-line setting (1009), which the company previously reported to have met its primary end-point. This data reinforces Calquence as a leading second-generation BTKi in this setting, and notably could expand its label to include fixed duration use as an alternative approach to continuous therapy, offering an alternative, shorter-duration regimen for patients. 3. In 2L+ relapsed/refractory multiple myeloma, GSK will present the overall survival (OS) data for the first time from a planned interim analysis of the Phase 3 DREAMM-7 trial (772), evaluating belantamab mafodotin (Blenrep) in combination with bortezomib plus dexamethasone (BorDex) following the announcement of the positive results in November 2024. Positive OS results will add to the evidence of clinical benefit, which could increase confidence in the ADC following its prior withdrawal from the market. GSK has submitted the data, along with DREAMM-8 (belantamab + pomdex), to the regulatory authorities. Relaunch of the ADC could offer an off-the-shelf option for patients with limited access to CAR-T/bispecific antibodies. Let us know what you’re excited to see at this year’s ASH conference! Visit the Deallus website to find out more: https://www.deallus.com/ #ASH #Hematology #conference #innovation #insights